Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer Feb 12, 2026 08:00AM
Oncopeptides' PEPAXTO ® Receives a Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care Jul 13, 2021 10:25AM
Oncopeptides shares updated results from the phase 3 OCEAN study based upon further analysis Jul 8, 2021 11:04AM
Phase 3 OCEAN study demonstrates that melphalan flufenamide is at least as efficacious as pomalidomide, the most used medicine in relapsed refractory multiple myeloma May 26, 2021 08:43AM
Oncopeptides announces three abstracts accepted by the 2021 American Society of Clinical Oncology May 19, 2021 07:25PM


May 5, 2021 08:00AM Oncopeptides Completes Patient Enrollment in Phase 2 PORT Study
Mar 22, 2021 07:39AM Oncopeptides Announces National Comprehensive Cancer Network® Adds PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical Practice Guidelines
Mar 15, 2021 08:17AM Oncopeptides Announces Commercial Availability of PEPAXTO® (melphalan flufenamide)
Mar 1, 2021 07:40AM FDA Approves Oncopeptides´ PEPAXTO® (melphalan flufenamide) for Patients with Triple-Class Refractory Multiple Myeloma